Dendreon Corp (DNDN) 0.13 $DNDN
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 124.76 (-1.64), NWBO: 7.63 (-0.19), GILD: 102.29 (+0.85), DNDN: 0.13 (-0.02), ICPT: 290.98 (+2.47), JUNO: 61.53 (+1.85), GALE: 1.46 (-0.03), AGIO: 107.97 (-2.99), AEGR: 27.20 (-0.20), ABBV: 60.40 (-0.79), BMY: 67.76 (-0.56), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 131.00 (-3.25), MYGN: 37.03 (-0.13), DNDN: 0.13 (-0.02), CTIC: 1.93 (unch), REGN: 488.87 (+2.85), CELG: 128.50 (+3.17)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 7.63 (-0.19), DNDN: 0.13 (-0.02), RTRX: 22.34 (+0.17), CYTR: 3.35 (+0.04), RPRX: 8.98 (-0.26), GALE: 1.46 (-0.03), AEGR: 27.20 (-0.20)
Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions
at The Street - Sat Dec 06, 12:00PM CST
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
BLUE: 124.76 (-1.64), KITE: 71.89 (-1.62), DNDN: 0.13 (-0.02), NVS: 101.68 (+1.81), CELG: 128.50 (+3.17)
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal.
DNDN: 0.13 (-0.02), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56)
Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST
NWBO: 7.63 (-0.19), DNDN: 0.13 (-0.02)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.25 (+0.20), GILD: 102.29 (+0.85), FB: 83.80 (+1.05), DNDN: 0.13 (-0.02), MSFT: 42.88 (+0.60), INTC: 31.31 (+0.57), GRPN: 7.60 (-0.04), AAPL: 125.90 (-1.60), CSCO: 28.44 (+0.18)
Will Patterson Companies (PDCO) Surprise Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:40PM CST
Patterson Companies (PDCO) had a mixed first quarter in which revenues beat the Zacks Consensus Estimate while adjusted earnings fell shy.
KR: 76.83 (+0.43), DNDN: 0.13 (-0.02), BBY: 40.79 (-0.81), PDCO: 50.34 (+0.52)
Market Maker Surveillance Report. DNDN, YHOO, CRDC, FNMAS, SLTD, BABA, Highest Net Sell Volume and Negative Price Friction For Thursday, November 13th 2014
M2 - Fri Nov 14, 3:02AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4759 companies with "abnormal" market making, 1814 companies with positive Friction Factors and 3114 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dendreon Corp (NASDAQ NDN), Yahoo! Inc (NASDAQ:YHOO), Cardica Inc (NASDAQ:CRDC), Federal National Mortgage Association Fannie Mae (OTC:FNMAS), Solar3D Inc (OTC:SLTD), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
YHOO: 45.03 (+0.05), DNDN: 0.13 (-0.02), CRDC: 0.61 (+0.01), SLTD: 3.15 (+0.36), BABA: 85.20 (-0.54)
Political Intelligence Rules Urged On D.C. Insiders
at Investor's Business Daily - Thu Nov 13, 5:54PM CST
The term "political intelligence" may sound like an oxymoron, but it can make a difference in investors' portfolios and has drawn the eye of legislators and investigators. Political intelligence is the business of people providing information about...
DNDN: 0.13 (-0.02), UNH: 119.14 (-1.62), AET: 108.63 (+0.32), HUM: 182.79 (+1.83)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 131.00 (-3.25), GILD: 102.29 (+0.85), ACHN: 11.06 (-0.36), DNDN: 0.13 (-0.02), AMGN: 170.10 (+0.99), ABBV: 60.40 (-0.79), REGN: 488.87 (+2.85)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ NDN), and Juniper (NYSE:JNPR).
GILD: 102.29 (+0.85), DNDN: 0.13 (-0.02), ZNGA: 2.70 (+0.05), AAPL: 125.90 (-1.60), JNPR: 23.68 (+0.03), BABA: 85.20 (-0.54)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 2.12 (-0.08), LSBK: 13.35 (-0.15), VSAR: 20.35 (+0.36), SANW: 4.27 (-0.08), URRE: 1.42 (+0.06), EDUC: 4.03 (+0.06), MCEP: 5.43 (+0.14), CYAN: 8.72 (-0.19), DNDN: 0.13 (-0.02), SUMR: 2.53 (-0.10), CRTN: 3.40 (+0.16)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 135.56 (+1.09), AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), DNDN: 0.13 (-0.02)
Update: Dendreon Bankruptcy
Alexander Maxwell - at Seeking Alpha - Tue Nov 11, 12:55PM CST
DNDN: 0.13 (-0.02)
Clarification: Dendreon-Chapter 11 Filing story
By The Associated Press - AP - Tue Nov 11, 12:43PM CST
In a story Nov. 10, The Associated Press reported that Bank of New York Mellon was listed as the largest creditor in a Chapter 11 bankruptcy court filing involving the drugmaker Dendreon Corp. BNY Mellon administers $620 million in notes for investors; it does not own them.
DNDN: 0.13 (-0.02)
Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 124.76 (-1.64), NWBO: 7.63 (-0.19), GILD: 102.29 (+0.85), DNDN: 0.13 (-0.02), ICPT: 290.98 (+2.47), JUNO: 61.53 (+1.85), GALE: 1.46 (-0.03), AGIO: 107.97 (-2.99), AEGR: 27.20 (-0.20), ABBV: 60.40 (-0.79), BMY: 67.76 (-0.56), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 131.00 (-3.25), MYGN: 37.03 (-0.13), DNDN: 0.13 (-0.02), CTIC: 1.93 (unch), REGN: 488.87 (+2.85), CELG: 128.50 (+3.17)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 7.63 (-0.19), DNDN: 0.13 (-0.02), RTRX: 22.34 (+0.17), CYTR: 3.35 (+0.04), RPRX: 8.98 (-0.26), GALE: 1.46 (-0.03), AEGR: 27.20 (-0.20)
Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions
at The Street - Sat Dec 06, 12:00PM CST
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
BLUE: 124.76 (-1.64), KITE: 71.89 (-1.62), DNDN: 0.13 (-0.02), NVS: 101.68 (+1.81), CELG: 128.50 (+3.17)
A New Combined Approach to Cancer Immunotherapy is Needed
ACCESSWIRE - Mon Dec 01, 11:35AM CST
NEW YORK, NY / ACCESSWIRE / December 1, 2014 / With the recent bankruptcy of Dendreon Corporation (NASDAQ
NDN) due to disappointing sales of its flagship Provenge prostate cancer vaccine, the future of cancer immunotherapy just got a bit cloudier. While Provenge itself will survive, Dendreon may end up going private in a debt restructuring deal. DNDN: 0.13 (-0.02), AMGN: 170.10 (+0.99), LLY: 76.12 (+1.90), BMY: 67.76 (-0.56)
Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST
NWBO: 7.63 (-0.19), DNDN: 0.13 (-0.02)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 16.25 (+0.20), GILD: 102.29 (+0.85), FB: 83.80 (+1.05), DNDN: 0.13 (-0.02), MSFT: 42.88 (+0.60), INTC: 31.31 (+0.57), GRPN: 7.60 (-0.04), AAPL: 125.90 (-1.60), CSCO: 28.44 (+0.18)
Will Patterson Companies (PDCO) Surprise Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 4:40PM CST
Patterson Companies (PDCO) had a mixed first quarter in which revenues beat the Zacks Consensus Estimate while adjusted earnings fell shy.
KR: 76.83 (+0.43), DNDN: 0.13 (-0.02), BBY: 40.79 (-0.81), PDCO: 50.34 (+0.52)
Market Maker Surveillance Report. DNDN, YHOO, CRDC, FNMAS, SLTD, BABA, Highest Net Sell Volume and Negative Price Friction For Thursday, November 13th 2014
M2 - Fri Nov 14, 3:02AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4759 companies with "abnormal" market making, 1814 companies with positive Friction Factors and 3114 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Thursday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Dendreon Corp (NASDAQ
NDN), Yahoo! Inc (NASDAQ:YHOO), Cardica Inc (NASDAQ:CRDC), Federal National Mortgage Association Fannie Mae (OTC:FNMAS), Solar3D Inc (OTC:SLTD), (NYSE:BABA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . YHOO: 45.03 (+0.05), DNDN: 0.13 (-0.02), CRDC: 0.61 (+0.01), SLTD: 3.15 (+0.36), BABA: 85.20 (-0.54)
Political Intelligence Rules Urged On D.C. Insiders
at Investor's Business Daily - Thu Nov 13, 5:54PM CST
The term "political intelligence" may sound like an oxymoron, but it can make a difference in investors' portfolios and has drawn the eye of legislators and investigators. Political intelligence is the business of people providing information about...
DNDN: 0.13 (-0.02), UNH: 119.14 (-1.62), AET: 108.63 (+0.32), HUM: 182.79 (+1.83)
Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 131.00 (-3.25), GILD: 102.29 (+0.85), ACHN: 11.06 (-0.36), DNDN: 0.13 (-0.02), AMGN: 170.10 (+0.99), ABBV: 60.40 (-0.79), REGN: 488.87 (+2.85)
Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - Wed Nov 12, 7:45AM CST
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ
NDN), and Juniper (NYSE:JNPR). GILD: 102.29 (+0.85), DNDN: 0.13 (-0.02), ZNGA: 2.70 (+0.05), AAPL: 125.90 (-1.60), JNPR: 23.68 (+0.03), BABA: 85.20 (-0.54)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HEAR: 2.12 (-0.08), LSBK: 13.35 (-0.15), VSAR: 20.35 (+0.36), SANW: 4.27 (-0.08), URRE: 1.42 (+0.06), EDUC: 4.03 (+0.06), MCEP: 5.43 (+0.14), CYAN: 8.72 (-0.19), DNDN: 0.13 (-0.02), SUMR: 2.53 (-0.10), CRTN: 3.40 (+0.16)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 135.56 (+1.09), AGN: 240.22 (+2.88), JNJ: 102.40 (+0.71), DNDN: 0.13 (-0.02)
Update: Dendreon Bankruptcy
Alexander Maxwell - at Seeking Alpha - Tue Nov 11, 12:55PM CST
DNDN: 0.13 (-0.02)
Clarification: Dendreon-Chapter 11 Filing story
By The Associated Press - AP - Tue Nov 11, 12:43PM CST
In a story Nov. 10, The Associated Press reported that Bank of New York Mellon was listed as the largest creditor in a Chapter 11 bankruptcy court filing involving the drugmaker Dendreon Corp. BNY Mellon administers $620 million in notes for investors; it does not own them.
DNDN: 0.13 (-0.02)
Bankruptcies, Breakouts, and Busts; What's Happening in Biotech?
ACCESSWIRE - Tue Nov 11, 10:34AM CST
CORAL GABLES, FL / ACCESSWIRE / November 11, 2014 / From prostate cancer drugs to stem-cell therapy, the biotech industry seems to encompass a variety of unique and innovative companies. According to market research firm IBISWorld, the global revenue of the Biotech industry is nearly $300 billion. Statista reports that more that $50Billion of US biopharmaceutical goods are exported and the industry is on pace to grow at a compounded annual rate of nearly 11%. IBIS notes that many small companies, alongside a few industry giants in pharmaceutical, chemical and agricultural firms, populate the global biotech industry. There is also a lower level of market share concentration as noted by IBISWorld estimates that the top four industry players will account for less than 28% of the industry's revenue in 2014. With so much potential there are certainly companies in the market, which have progressed to the next level and others that have mismanaged their businesses into bankruptcy.
DNDN: 0.13 (-0.02)
